23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference Download PDF Post navigationPreviousPrevious post:Positive results of the Phase 2 study evaluating masitinib in Covid-19NextNext post:AB Science provides an update on the microtubule program AB8939Related PostsRevenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024AB Science provides an update on the microtubule program AB8939September 26, 2024Positive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
